Sleep aid toxicosis in dogs: 317 cases (2004-2010)

Adam R. Lancaster, Justine A. Lee, Lynn R. Hovda, Brian Hardy, Lee X. Miyahara, Elizabeth P. Martin, Megan F. Whelan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To summarize the signalment, clinical signs observed, time to onset of clinical signs, duration of clinical signs, and the outcome in a large case series of nonbenzodiazepine sleep aid ingestions in dogs, including 2 sleep aids that have not been previously described in the veterinary literature. Design: Retrospective study conducted between 2004 and 2010. Setting: An animal poison control center based out of Bloomington, MN. Animals: During this time frame, 453 cases were identified involving 467 dogs. Of these cases, 150 cases were excluded due to incomplete medical records, multipet households, or the inability to calculate a dose exposure. A total of 317 dogs with presumed sleep aid medication toxicosis were included. Interventions: None. Measurements and Main Results: Records of dogs with sleep aid medication toxicosis identified by a review of an animal poison control center electronic database were evaluated. The most common sleep aid medications ingested were zolpidem (240/317 [75.7%]), eszopiclone (62/317 [19.5%]), and zaleplon (15/317 [4.7%]). Overall, clinical signs developed in 36% of patients (115/317), while 64% (202/317) remained asymptomatic. The most common organ systems affected and clinical signs seen involved the central nervous system (eg, agitation, sedation) and gastrointestinal tract (eg, anorexia, hypersalivation, vomiting). Conclusions: Overall, the prognosis for dogs with sleep aid medication toxicosis was excellent, and no fatalities were reported in this clinical population. As significant clinical signs can still be seen with ingestion, appropriate decontamination is warranted in asymptomatic patients via emesis or gastric lavage, followed by activated charcoal administration. Symptomatic patients should be hospitalized for monitoring and supportive care for a minimum of 12 hours or until clinical signs resolve.

Original languageEnglish (US)
Pages (from-to)658-665
Number of pages8
JournalJournal of Veterinary Emergency and Critical Care
Volume21
Issue number6
DOIs
StatePublished - Dec 1 2011
Externally publishedYes

Fingerprint

sleep
poisoning
Sleep
Dogs
drug therapy
dogs
Poison Control Centers
zaleplon
Vomiting
Eating
ingestion
Gastric Lavage
Sialorrhea
animals
Decontamination
Charcoal
decontamination
agitation
Anorexia
sedation

Keywords

  • Benzodiazepine
  • Insomnia medication
  • Intoxication
  • Sedatives

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Lancaster, A. R., Lee, J. A., Hovda, L. R., Hardy, B., Miyahara, L. X., Martin, E. P., & Whelan, M. F. (2011). Sleep aid toxicosis in dogs: 317 cases (2004-2010). Journal of Veterinary Emergency and Critical Care, 21(6), 658-665. https://doi.org/10.1111/j.1476-4431.2011.00694.x

Sleep aid toxicosis in dogs : 317 cases (2004-2010). / Lancaster, Adam R.; Lee, Justine A.; Hovda, Lynn R.; Hardy, Brian; Miyahara, Lee X.; Martin, Elizabeth P.; Whelan, Megan F.

In: Journal of Veterinary Emergency and Critical Care, Vol. 21, No. 6, 01.12.2011, p. 658-665.

Research output: Contribution to journalArticle

Lancaster, AR, Lee, JA, Hovda, LR, Hardy, B, Miyahara, LX, Martin, EP & Whelan, MF 2011, 'Sleep aid toxicosis in dogs: 317 cases (2004-2010)', Journal of Veterinary Emergency and Critical Care, vol. 21, no. 6, pp. 658-665. https://doi.org/10.1111/j.1476-4431.2011.00694.x
Lancaster, Adam R. ; Lee, Justine A. ; Hovda, Lynn R. ; Hardy, Brian ; Miyahara, Lee X. ; Martin, Elizabeth P. ; Whelan, Megan F. / Sleep aid toxicosis in dogs : 317 cases (2004-2010). In: Journal of Veterinary Emergency and Critical Care. 2011 ; Vol. 21, No. 6. pp. 658-665.
@article{86fd79370cbe4c7793b8385a0dee6a91,
title = "Sleep aid toxicosis in dogs: 317 cases (2004-2010)",
abstract = "Objective: To summarize the signalment, clinical signs observed, time to onset of clinical signs, duration of clinical signs, and the outcome in a large case series of nonbenzodiazepine sleep aid ingestions in dogs, including 2 sleep aids that have not been previously described in the veterinary literature. Design: Retrospective study conducted between 2004 and 2010. Setting: An animal poison control center based out of Bloomington, MN. Animals: During this time frame, 453 cases were identified involving 467 dogs. Of these cases, 150 cases were excluded due to incomplete medical records, multipet households, or the inability to calculate a dose exposure. A total of 317 dogs with presumed sleep aid medication toxicosis were included. Interventions: None. Measurements and Main Results: Records of dogs with sleep aid medication toxicosis identified by a review of an animal poison control center electronic database were evaluated. The most common sleep aid medications ingested were zolpidem (240/317 [75.7{\%}]), eszopiclone (62/317 [19.5{\%}]), and zaleplon (15/317 [4.7{\%}]). Overall, clinical signs developed in 36{\%} of patients (115/317), while 64{\%} (202/317) remained asymptomatic. The most common organ systems affected and clinical signs seen involved the central nervous system (eg, agitation, sedation) and gastrointestinal tract (eg, anorexia, hypersalivation, vomiting). Conclusions: Overall, the prognosis for dogs with sleep aid medication toxicosis was excellent, and no fatalities were reported in this clinical population. As significant clinical signs can still be seen with ingestion, appropriate decontamination is warranted in asymptomatic patients via emesis or gastric lavage, followed by activated charcoal administration. Symptomatic patients should be hospitalized for monitoring and supportive care for a minimum of 12 hours or until clinical signs resolve.",
keywords = "Benzodiazepine, Insomnia medication, Intoxication, Sedatives",
author = "Lancaster, {Adam R.} and Lee, {Justine A.} and Hovda, {Lynn R.} and Brian Hardy and Miyahara, {Lee X.} and Martin, {Elizabeth P.} and Whelan, {Megan F.}",
year = "2011",
month = "12",
day = "1",
doi = "10.1111/j.1476-4431.2011.00694.x",
language = "English (US)",
volume = "21",
pages = "658--665",
journal = "Journal of Veterinary Emergency and Critical Care",
issn = "1479-3261",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Sleep aid toxicosis in dogs

T2 - 317 cases (2004-2010)

AU - Lancaster, Adam R.

AU - Lee, Justine A.

AU - Hovda, Lynn R.

AU - Hardy, Brian

AU - Miyahara, Lee X.

AU - Martin, Elizabeth P.

AU - Whelan, Megan F.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Objective: To summarize the signalment, clinical signs observed, time to onset of clinical signs, duration of clinical signs, and the outcome in a large case series of nonbenzodiazepine sleep aid ingestions in dogs, including 2 sleep aids that have not been previously described in the veterinary literature. Design: Retrospective study conducted between 2004 and 2010. Setting: An animal poison control center based out of Bloomington, MN. Animals: During this time frame, 453 cases were identified involving 467 dogs. Of these cases, 150 cases were excluded due to incomplete medical records, multipet households, or the inability to calculate a dose exposure. A total of 317 dogs with presumed sleep aid medication toxicosis were included. Interventions: None. Measurements and Main Results: Records of dogs with sleep aid medication toxicosis identified by a review of an animal poison control center electronic database were evaluated. The most common sleep aid medications ingested were zolpidem (240/317 [75.7%]), eszopiclone (62/317 [19.5%]), and zaleplon (15/317 [4.7%]). Overall, clinical signs developed in 36% of patients (115/317), while 64% (202/317) remained asymptomatic. The most common organ systems affected and clinical signs seen involved the central nervous system (eg, agitation, sedation) and gastrointestinal tract (eg, anorexia, hypersalivation, vomiting). Conclusions: Overall, the prognosis for dogs with sleep aid medication toxicosis was excellent, and no fatalities were reported in this clinical population. As significant clinical signs can still be seen with ingestion, appropriate decontamination is warranted in asymptomatic patients via emesis or gastric lavage, followed by activated charcoal administration. Symptomatic patients should be hospitalized for monitoring and supportive care for a minimum of 12 hours or until clinical signs resolve.

AB - Objective: To summarize the signalment, clinical signs observed, time to onset of clinical signs, duration of clinical signs, and the outcome in a large case series of nonbenzodiazepine sleep aid ingestions in dogs, including 2 sleep aids that have not been previously described in the veterinary literature. Design: Retrospective study conducted between 2004 and 2010. Setting: An animal poison control center based out of Bloomington, MN. Animals: During this time frame, 453 cases were identified involving 467 dogs. Of these cases, 150 cases were excluded due to incomplete medical records, multipet households, or the inability to calculate a dose exposure. A total of 317 dogs with presumed sleep aid medication toxicosis were included. Interventions: None. Measurements and Main Results: Records of dogs with sleep aid medication toxicosis identified by a review of an animal poison control center electronic database were evaluated. The most common sleep aid medications ingested were zolpidem (240/317 [75.7%]), eszopiclone (62/317 [19.5%]), and zaleplon (15/317 [4.7%]). Overall, clinical signs developed in 36% of patients (115/317), while 64% (202/317) remained asymptomatic. The most common organ systems affected and clinical signs seen involved the central nervous system (eg, agitation, sedation) and gastrointestinal tract (eg, anorexia, hypersalivation, vomiting). Conclusions: Overall, the prognosis for dogs with sleep aid medication toxicosis was excellent, and no fatalities were reported in this clinical population. As significant clinical signs can still be seen with ingestion, appropriate decontamination is warranted in asymptomatic patients via emesis or gastric lavage, followed by activated charcoal administration. Symptomatic patients should be hospitalized for monitoring and supportive care for a minimum of 12 hours or until clinical signs resolve.

KW - Benzodiazepine

KW - Insomnia medication

KW - Intoxication

KW - Sedatives

UR - http://www.scopus.com/inward/record.url?scp=84861420037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861420037&partnerID=8YFLogxK

U2 - 10.1111/j.1476-4431.2011.00694.x

DO - 10.1111/j.1476-4431.2011.00694.x

M3 - Article

C2 - 22316259

AN - SCOPUS:84861420037

VL - 21

SP - 658

EP - 665

JO - Journal of Veterinary Emergency and Critical Care

JF - Journal of Veterinary Emergency and Critical Care

SN - 1479-3261

IS - 6

ER -